Bioengineered MSCs expressing proteins such as NK4, which inhibits hepatocyte growth factor (HGF), or thrombospondin-1 (TSP-1) variants, which suppress angiogenesis, have shown promising results in reducing tumour growth and vascularization in a lung metastatic and a glioblastoma tumour model, respectively [126,142,143]. Here, HGF is linked to neoplasm.